Abstract
The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Current Drug Targets
Title:The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Volume: 13 Issue: 5
Author(s): Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella
Affiliation:
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Abstract: The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Export Options
About this article
Cite this article as:
Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella , The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800399008
DOI https://dx.doi.org/10.2174/138945012800399008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews The Pediatrician as Smoking Cessation Counselor: Rationale and Review of the Literature
Current Pediatric Reviews Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract
Current Pharmaceutical Design An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Inflammation and Coagulation in Urticaria and Angioedema
Current Vascular Pharmacology Preparation and Characterization of Gastro-retentive Sustained Release Microcapsules of Salbutamol Sulphate
Drug Delivery Letters PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research
Current Medicinal Chemistry Medical Treatment of COPD Patients with Mild and Moderate Airflow Obstruction
Current Respiratory Medicine Reviews Current Status and Future Prospects for Research on Tyrosine Sulfation
Current Pharmaceutical Biotechnology The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Cloning and the Allergenic Characterization of Tropomyosin from Tyrophagus putrescentiae
Protein & Peptide Letters P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future
Current Pharmaceutical Design Relevance of Cat and Dog Sensitization by Skin Prick Testing in Childhood Eczema and Asthma
Current Pediatric Reviews Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19
Protein & Peptide Letters Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Eosinophilic Esophagitis: New Pathogenic Insights
Current Immunology Reviews (Discontinued) Modified Pulsincap of Ibuprofen - A Novel Approach for Chronotherapy
Current Drug Delivery Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) Physicochemical, Pharmacological and Pharmacokinetic Properties of the Zwitterionic Antihistamines Cetirizine and Levocetirizine
Current Medicinal Chemistry